Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

Danish Head and Neck Cancer Group · 2007
ClinicalTrials.gov · Datasets · License: Public Domain · 2007
Open Source ↗
antibodyradiotherapy
cancer of the head and neck, squamous cell carcinomas of the head and neck, epidermal growth factor receptor, antibody, radiotherapy, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 1031354
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.